{"slug":"bpc-kpv-ibd-crohns-colitis","verification":{"valid":true,"entries":27,"head":"a782bc50620a80497cdf00d1cdef66a9499231d617b2f3c7a93bd169dd2ed94e"},"energy":{"passes":27,"tokens_in":14340,"tokens_out":1957,"tokens_total":16297,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":9,"system/audit-repair":11,"kimi/moonshot-v1-8k":1,"gemini/gemini-2.5-flash":1,"repair":1,"fill-slots":1,"owner":1},"head":"a782bc50620a80497cdf00d1cdef66a9499231d617b2f3c7a93bd169dd2ed94e"},"provenance":[{"ts":"2026-06-29T09:09:10.441Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: BPC-157 + KPV for IBD, Crohn's Disease, and Colitis\n\nAudience: 3M diagnosed. Same mechanism as above; more specific audience. Novelty: 8/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"bpc-157-kpv-ibd-crohns-colitis\",\n  \"title\": \"BPC-157 and KPV for IBD, Crohn's Disease, and Colitis: Preclinical Evidence Review\",\n  \"body\": \"## Overview of Peptides in Gut Models\\n\\nBPC-157 is described as promoting local angiogenesis and tissue repair in damaged areas. KPV is described as providing gut-specific anti-inflammatory effects without systemic immune suppression.\\n\\n## BPC-157 in Colitis and IBD Models\\n\\n### Rat Studies (Preclinical)\\n\\nIn a rat model of cysteamine-induced colitis combined with colon-colon anastomosis, BPC-157 (10 µg/kg or 10 ng/kg, intraperitoneal or oral) promoted healing of colitis lesions and anastomosis where controls did not. [Source from search]\\n\\nBPC-157 cured rat ischemic colitis at early and late time points under various conditions.\\n\\nPreclinical models indicate BPC-157 improved outcomes in inflammatory bowel disease models, GI ulcers, and anastomotic sites.\\n\\nNo human clinical trial data identified for IBD, Crohn's, or colitis.\\n\\n## KPV in Colitis Models\\n\\n### Murine Studies (Preclinical)\\n\\nIn two murine models of colitis (DSS and CD45RBhi transfer), KPV treatment led to earlier recovery, body weight regain, reduced inflammatory infiltrates, and lower myeloperoxidase activity. Effects observed even in MC1R non-functional mice.\\n\\nKPV showed significant anti-inflammatory effects in murine colitis models, suggested as a potential therapeutic option for IBD.\\n\\nKPV uptake via PepT1 transporter noted in IBD contexts.\\n\\nNo human clinical trial data identified.\\n\\n## Combination Considerations\\n\\nPreclinical and mechanistic sources discuss BPC-157 for structural repair alongside KPV for localized inflammation reduction. No dedicated combination studies in IBD models located.\\n\\n## Evidence Summary\\n\\nAll available data are from animal (rat/murine) studies or mechanistic descriptions. No human data located for these indications or peptides in IBD populations. Repair-focused mechanisms distinguished from suppressi","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"9495d67e0547252b2ecc5936b0b3f58de29612456a9200952eb01fcf4a489d1d"},{"ts":"2026-06-29T10:58:20.080Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9495d67e0547252b2ecc5936b0b3f58de29612456a9200952eb01fcf4a489d1d","hash":"c70b957757f2e4a230a1784b84d36413b1532850713da8d55b79c42004803a3a"},{"ts":"2026-06-29T10:58:46.448Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c70b957757f2e4a230a1784b84d36413b1532850713da8d55b79c42004803a3a","hash":"eff160e53a07054ac240752f6fdb0ac613ed3fefcd601915385f905388705c1c"},{"ts":"2026-06-29T10:59:07.146Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"eff160e53a07054ac240752f6fdb0ac613ed3fefcd601915385f905388705c1c","hash":"2875e9d3d1e8a3ee1e99641ecf18a97e664144010faed12cb4147651b2ccbb79"},{"ts":"2026-06-29T10:59:35.843Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2875e9d3d1e8a3ee1e99641ecf18a97e664144010faed12cb4147651b2ccbb79","hash":"9a1bee2a9be20c23d92d012343f39d01cf8dc9f6e6969d4ad3bd6e78bf0a43b2"},{"ts":"2026-06-29T11:00:18.293Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9a1bee2a9be20c23d92d012343f39d01cf8dc9f6e6969d4ad3bd6e78bf0a43b2","hash":"d7cd399e4ee2f546e708672cdd2f2e93baae3db137353c6e1e2b0eb5c3491f4c"},{"ts":"2026-06-29T12:48:37.912Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d7cd399e4ee2f546e708672cdd2f2e93baae3db137353c6e1e2b0eb5c3491f4c","hash":"7a2a550af9d45673624e430ee7c40b4433a1cd701a624f00d5f602d522845f21"},{"ts":"2026-06-29T12:48:38.480Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ibd-crohns-colitis c28","response":"BPC-157 and KPV for IBD, Crohn's Disease, and Colitis: Preclinical Evidence Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7a2a550af9d45673624e430ee7c40b4433a1cd701a624f00d5f602d522845f21","hash":"a5bbb7c9cc14f2a30dc760efcebf836ce9baee4ac43bd2b906be8b9a2d4ede0e"},{"ts":"2026-06-29T12:48:38.523Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ibd-crohns-colitis c29","response":"Per this ledger on BPC-157 and KPV for IBD, Crohn's Disease, and Colitis: Preclinical Evidence Review: 17 scientific and 10 anecdotal sources are catalogued; 6 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a5bbb7c9cc14f2a30dc760efcebf836ce9baee4ac43bd2b906be8b9a2d4ede0e","hash":"2336baedce7d3a5af9b71de4f1abfb3470458107eae284313a858d5099bb1638"},{"ts":"2026-06-29T12:48:38.564Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ibd-crohns-colitis c30","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2336baedce7d3a5af9b71de4f1abfb3470458107eae284313a858d5099bb1638","hash":"ee1f1474576ae75e34a0349bba9d00a59c11f27954e7360a31f1a6fcfc522321"},{"ts":"2026-06-29T12:48:38.611Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ibd-crohns-colitis c31","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ee1f1474576ae75e34a0349bba9d00a59c11f27954e7360a31f1a6fcfc522321","hash":"733df8cbe21d97f46642a78e6488f75e77cdeb2fee706431b30a9dc497bd2743"},{"ts":"2026-06-29T12:48:38.662Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ibd-crohns-colitis c32","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"733df8cbe21d97f46642a78e6488f75e77cdeb2fee706431b30a9dc497bd2743","hash":"b3e98278a37599d02cc6d9f931c51bd9a40a8e9b759eed319a0a730f3a86ea29"},{"ts":"2026-06-29T12:48:39.370Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b3e98278a37599d02cc6d9f931c51bd9a40a8e9b759eed319a0a730f3a86ea29","hash":"91f99c78ed099e2f6c2c0b84d1cfe5490f879e4c2e05b54d8d446de3f0a13825"},{"ts":"2026-06-29T13:23:35.774Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"91f99c78ed099e2f6c2c0b84d1cfe5490f879e4c2e05b54d8d446de3f0a13825","hash":"d6e2a6e4e06bb59a7cdfc3c800b7f4926b69823c5b978fafad814ded18a2bfdb"},{"ts":"2026-06-29T13:23:37.082Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d6e2a6e4e06bb59a7cdfc3c800b7f4926b69823c5b978fafad814ded18a2bfdb","hash":"098628813dcf7ee9fef42c3b55e00a6b7e7dbaa3a7aeed2949b7cee0eef8d79e"},{"ts":"2026-06-29T13:38:45.334Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"I am adding explicit gaps regarding what is unknown in the current evidence base and naming who claims what from anecdotes where this information is missing. This is in line with the instructions to state explicit gaps and name who claims what from anecdotes if missing. I am not Grok because I am adding claims based on the instructions and the provided topology, rather than inventing new claims or sources.","tokens_in":3222,"tokens_out":362,"cost":0,"prev":"098628813dcf7ee9fef42c3b55e00a6b7e7dbaa3a7aeed2949b7cee0eef8d79e","hash":"011ad16c979b6af0329fc02a3ae9346f7bb29de20a2aaf8b1dcb00bbe9e67c60"},{"ts":"2026-06-29T13:54:09.105Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"011ad16c979b6af0329fc02a3ae9346f7bb29de20a2aaf8b1dcb00bbe9e67c60","hash":"185831bc5cdeb03489d533cc87149dd18c4f9f215e135f4bf127da40daafaba2"},{"ts":"2026-06-29T13:54:10.262Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"185831bc5cdeb03489d533cc87149dd18c4f9f215e135f4bf127da40daafaba2","hash":"05a5d3b75fa37b6a3daf3a79523d0b71b13a0d327da0a84f3dd9f0521e609c6b"},{"ts":"2026-06-29T15:05:09.765Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"I, Gemini, have added three tier-honest claims to address gaps in the ledger, focusing on what is unknown and who claims what, as per instructions. I am not Grok; my purpose is to collaborate by identifying and filling specific information voids using only provided sources. I chose not to challenge any claims as there were no sufficiently weak claims with clear counter-evidence from the topology that weren't meta-claims about the ledger itself.","tokens_in":2947,"tokens_out":479,"cost":0,"prev":"05a5d3b75fa37b6a3daf3a79523d0b71b13a0d327da0a84f3dd9f0521e609c6b","hash":"85f26715dff5ef2fa1b57de39734092e1f14e91b32d6b172ee97ffd05ab6b7a5"},{"ts":"2026-06-29T16:13:26.989Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"85f26715dff5ef2fa1b57de39734092e1f14e91b32d6b172ee97ffd05ab6b7a5","hash":"d5b7b48900cdb0103cc911461ed2ef7a1f55b5d9eb8efd318e4696332c051085"},{"ts":"2026-06-29T16:14:09.303Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d5b7b48900cdb0103cc911461ed2ef7a1f55b5d9eb8efd318e4696332c051085","hash":"f977542a4f1e6fbe52f7b0d1b12145f6a4338f1be95ae1fc9277f5eacb260a18"},{"ts":"2026-06-29T16:14:39.909Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f977542a4f1e6fbe52f7b0d1b12145f6a4338f1be95ae1fc9277f5eacb260a18","hash":"80194d24841b856b8fd8177adcf72de1dc18dbd5482c2268e56b3b223c83ae2b"},{"ts":"2026-06-29T16:30:34.964Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"## Regeneration vs degeneration — where this fits\nThe gut lining breaks down and rebuilds every day. In IBD, Crohn's, and colitis, breakdown outruns repair. Inflammation stays high. Tissue stays damaged. Most drugs lower the inflammation signal but do not fix the lining. BPC-157 and KPV are studied for the repair side: one for tissue rebuilding, one for lowering gut inflammation.\n\n## What it is\nBPC-157 is a chain of 15 amino acids taken from a protein found in stomach juice. KPV is a short chain of three amino acids taken from a larger hormone. Both are studied in gut-damage models. Neither is approved as a drug.\n\n## How it works\nBPC-157 is linked to blood-vessel growth and cell movement to injury sites. KPV is linked to lower production of inflammatory signals inside gut cells. One study showed KPV travels through a gut transporter called PepT1. The two are often discussed together because one targets inflammation and the other targets tissue repair.\n\n## Why it would work (logic chain)\nStep 1: Ongoing inflammation damages the gut wall.  \nStep 2: Damaged wall lets more triggers in, so inflammation stays high.  \nStep 3: If inflammation drops and new cells can move in and form vessels, the wall can close.  \nStep 4: BPC-157 is studied for the vessel and cell-migration part. KPV is studied for the inflammation-drop part.  \nStep 5: If both steps happen at once, the cycle of damage may slow.\n\n## Why people take it\nPeople with Crohn's, ulcerative colitis, or colitis symptoms look for options when standard drugs do not fully stop flares or when they want to try something aimed at tissue repair. They read about the two peptides being used together for gut lining and inflammation control.\n\n## How many people take it\nExact numbers are unknown. The ledger contains 21 Reddit posts and 3 other anecdote sources that mention personal use. No large registry or prescription count exists.\n\n## Evidence inventory\n41 total sources.  \n17 studies or reviews catalogued.  \n21 Reddit posts.  ","tokens_in":8171,"tokens_out":1116,"cost":0,"prev":"80194d24841b856b8fd8177adcf72de1dc18dbd5482c2268e56b3b223c83ae2b","hash":"cb53aa008a8e5f319bfcb5d39d36ae5d59177addfc834c46f4e8d44c27f04980"},{"ts":"2026-06-29T18:17:42.787Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"cb53aa008a8e5f319bfcb5d39d36ae5d59177addfc834c46f4e8d44c27f04980","hash":"9635057990973601075d5654900e3ce8384b554d179838c90e45892500054ede"},{"ts":"2026-06-29T19:52:06.689Z","model":"repair","action":"repair","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":9}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9635057990973601075d5654900e3ce8384b554d179838c90e45892500054ede","hash":"c6870aac88310e71270940515a278bb966c4e83b51811134d222c5e89c19d863"},{"ts":"2026-06-29T21:03:01.920Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-kpv-ibd-crohns-colitis c58","response":"BPC-157 and KPV for IBD, Crohn's Disease, and Colitis: Preclinical Evidence Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c6870aac88310e71270940515a278bb966c4e83b51811134d222c5e89c19d863","hash":"4619145686202aefe9aa70517d501e97213bef423cf79382c3ae9f2ac6ecb852"},{"ts":"2026-07-17T02:38:42.016Z","model":"owner","action":"voxel_divide","prompt":"","input":"bpc-kpv-ibd-crohns-colitis","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4619145686202aefe9aa70517d501e97213bef423cf79382c3ae9f2ac6ecb852","hash":"a782bc50620a80497cdf00d1cdef66a9499231d617b2f3c7a93bd169dd2ed94e"}]}